keyword
https://read.qxmd.com/read/38494765/-expert-consensus-on-clinical-practice-of-egfr-exon20-insertion-detection-in-non-small-cell-lung-cancer-in-china-2024-edition
#1
JOURNAL ARTICLE
(no author information available yet)
About 82% of the Chinese lung cancer population is non-small cell lung cancer(NSCLC), and the epidermal growth factor receptor (EGFR) gene is the most common driver mutation in the Chinese lung cancer population (51.7%-54.4%). In recent years, the rapid development and wide application of targeted therapies, especially EGFR tyrosine kinase inhibitors, have significantly improved the survival time and quality of life of Chinese lung cancer patients. EGFR exon20 insertion (EGFR ex20ins) accounts for 0.3%-2.9% in NSCLC patients in China...
March 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38410222/the-safety-and-efficacy-of-anti-pd-1-inhibitor-based-combinational-therapy-in-non-small-cell-lung-cancer-patients-with-oncogenic-alterations
#2
JOURNAL ARTICLE
Lu Chen, Jingyuan Xie, Meiying Zhu, Dong Wang, Hongbin Liu, Ping Zhan, Jie Yin, Mingxiang Ye, Yong Song, Tangfeng Lv
BACKGROUND: The anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy has been extensively used in patients with non-small cell lung cancer (NSCLC) in which the tumors are negative for oncogenic alterations. However, whether PD-1/PD-L1 blockade therapy could be applicable in patients harboring oncogenic mutations is largely unknown. METHODS: In this retrospective study, we analyzed the safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in a NSCLC cohort of 84 patients who harbored oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), k-Ras, RET, HER2 and BRAF...
January 31, 2024: Translational Cancer Research
https://read.qxmd.com/read/38226415/efficacy-of-osimertinib-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-with-malignant-pleural-effusion
#3
JOURNAL ARTICLE
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
BACKGROUND: As an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), osimertinib has emerged as a standard EGFR-mutation positive treatment for non-small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudied. This study aimed to evaluate the impact of osimertinib on time to treatment failure (TTF) and overall survival (OS) in patients with EGFR-mutation positive NSCLC, comparing those with and without MPE...
January 16, 2024: Thoracic Cancer
https://read.qxmd.com/read/38012986/brief-report-real-world-efficacy-and-safety-of-amivantamab-for-egfr-mutant-non-small-cell-lung-cancer-nsclc
#4
JOURNAL ARTICLE
Kaiwen Wang, Robyn Du, Nathaniel J Myall, Whitney E Lewis, Natalie Uy, Lingzhi Hong, Ferdinandos Skoulidis, Lauren A Byers, Anne Tsao, Tina Cascone, Jenny Pozadzides, Janet Tu, Marcelo V Negrao, Don L Gibbons, Keunchil Park, Waree Rinsurongkawong, J Jack Lee, David Gandara, Deepti Behl, Catherine A Shu, Jonathan W Riess, Christina Baik, Heather A Wakelee, Ara A Vaporciyan, John V Heymach, Jianjun Zhang, Xiuning Le
BACKGROUND: Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations, after prior therapy. However, the benefits and safety of amivantamab in other EGFR-mutation lung cancer, with or without osimertinib, and with concurrent radiation therapy, are less known. METHODS: We queried the MD Anderson Lung Cancer GEMINI, Fred Hutchinson Cancer Research Center, University of California Davis Comprehensive Cancer Center and Stanford Cancer Center's database for patients with EGFR-mutant NSCLC treated with amivantamab, not on a clinical trial...
November 25, 2023: Journal of Thoracic Oncology
https://read.qxmd.com/read/38001033/prognostic-outcomes-and-recurrence-patterns-in-resected-stage-i-lung-adenocarcinoma-harboring-atypical-epidermal-growth-factor-receptor-mutation
#5
JOURNAL ARTICLE
Tao Chen, Jialiang Wen, Yingze Li, Jiajun Deng, Yifan Zhong, Likun Hou, Yunlang She, Dong Xie, Chang Chen
OBJECTIVES: Limited data exist on the characteristics of atypical EGFR mutation in early stage lung cancer. We aim to elucidate the associations with outcomes and recurrence patterns in resected stage I lung adenocarcinoma harboring atypical EGFR mutation. METHODS: Eligible patients between 2014 and 2019 were retrospectively identified and grouped into exon20 insertion mutation and major atypical mutation, which included G719X, L861Q, and S768I. Disease-free survival (DFS) was evaluated in the entire cohort and stratified by radiological characteristics...
November 24, 2023: European Journal of Cardio-thoracic Surgery
https://read.qxmd.com/read/37703723/egfr-exon20-insertion-mutations-in-non-small-cell-lung-cancer-clinical-implications-and-recent-advances-in-targeted-therapies
#6
REVIEW
Qianming Bai, Jialei Wang, Xiaoyan Zhou
The advent of targeted therapies for oncogenic mutations has led to a major paradigm shift in the management of non-small cell lung cancer (NSCLC). Molecular targets, such as epidermal growth factor receptor (EGFR)-activating mutations in the region of exons 18 through 21 are the most common oncogenic driver in NSCLC. Classical activating mutations, such as in-frame deletions in exon 19 and point mutations in exon 21 (L858R), are strong predictors for good clinical response to the approved EGFR-tyrosine kinase inhibitors (EGFR-TKIs)...
November 2023: Cancer Treatment Reviews
https://read.qxmd.com/read/37465107/long-lasting-benefit-on-multimodal-treatment-combining-osimertinib-and-stereotaxic-radiotherapy-for-metastatic-non-small-cell-lung-cancer-with-the-egfr-exon-20-insertion-773-774-hvdelinslm-a-case-report
#7
Aurélie Louvet, Natasha Honoré, Anne-France Dekairelle, Cédric Van Marcke, Jean-Charles Goeminne
A non-small-cell-lung-cancer patient with cerebral metastasis presenting an atypical exon 20 mutation in the EGFR gene had a long-lasting tumor cotrol on mulimodal treatment with osimertinib and stereotaxic radiotherapy on oligoprogressing lesions. Most exon-20 mutations are resistant to first, second and third generation EGFR-directed TKI. This case was discussed on our molecular tumour board. As the more specific exon-20 targeted therapies were not yet available and as sporadic short responses on the third generation EGFR-directed TKI, osimertinib had been described, the patient started osimertinib...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37284196/-egfr-and-erbb2-exon-20-insertion-duplication-in-advanced-non-small-cell-lung-cancer-genomic-profiling-and-clinicopathologic-features
#8
JOURNAL ARTICLE
Ramakrishna R Sompallae, Bilge Dundar, Natalya V Guseva, Aaron D Bossler, Deqin Ma
BACKGROUND: Exon 20 (ex20) in-frame insertions or duplications (ins/dup) in epidermal growth factor receptor ( EGFR ) and its analog erb-b2 receptor tyrosine kinase 2 ( ERBB2 ) are each detected in 1.5% of non-small cell lung cancer (NSCLC). Unlike EGFR p.L858R or ex19 deletions, ex20 ins/dup is associated with de novo resistance to classic EGFR inhibitors, lack of response to immune checkpoint inhibitors, and poor prognosis. US Food and Drug Administration has approved mobocertinib and amivantamab for targeting tumors with this aberration, but the number of comprehensive studies on ex20 ins/dup NSCLC is limited...
2023: Frontiers in Oncology
https://read.qxmd.com/read/36760378/-btn2a1-braf-fusion-may-be-a-novel-mechanism-of-resistance-to-osimertinib-in-lung-adenocarcinoma-a-case-report
#9
Wei-Min Kong, Yong-Jun Guo, Jie Ma, Chao Shi
BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR -TKI) indicated for NSCLC that effectively targets sensitive epidermal growth factor receptor mutation and exon20 T790M. Despite initially impressive outcomes, acquired resistance (AR) develops rapidly, typically within 9-13 months, and the mechanisms of resistance are not fully understood...
January 30, 2023: Translational Cancer Research
https://read.qxmd.com/read/36317157/spotlight-on-furmonertinib-alflutinib-ast2818-the-swiss-army-knife-del19-l858r-t790m-exon-20-insertions-uncommon-g719x-s768i-l861q-among-the-third-generation-egfr-tkis
#10
REVIEW
Shannon S Zhang, Sai-Hong Ignatius Ou
Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) treatment of advanced EGFR + NSCLC due to statistically significant improved progression-free survival (PFS) and overall survival (OS) compared with first-generation (1G) treatment from the FLAURA trial. Recently two other 3G EGFR TKIs (aumolertinib and furmonertinib) have been approved in China for treatment of EGFR T790M+ NSCLC. Randomized Phase 3 trials of these two 3G EGFR TKIs have also demonstrated PFS over gefitinib respectively...
2022: Lung Cancer: Targets and Therapy
https://read.qxmd.com/read/36119499/real-world-clinical-treatment-outcomes-in-chinese-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations
#11
JOURNAL ARTICLE
Chao Shi, Ruyue Xing, Mengmeng Li, Junnan Feng, Rui Sun, Bing Wei, Yongjun Guo, Jie Ma, Huijuan Wang
Background: EGFR exon 20 insertions ( EGFR ex20ins) constitute a heterogeneous subset of EGFR -activating alterations. However, the effectiveness of standard therapy in patients with EGFR ex20ins remains poor. Methods: In our study, we retrospectively collected next-generation sequencing (NGS) data from 7,831 Chinese NSCLC patients and analyzed the relationship between EGFR ex20ins variations and medical records. Results: Our data showed that EGFR ex20ins account for up to 3...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35739536/a-lung-adenocarcinoma-patient-with-co-mutations-of-met-and-egfr-exon20-insertion-responded-to-crizotinib
#12
JOURNAL ARTICLE
Yan Chen, Bo Jiang, Yuange He, Chu Zhang, Wenjie Zhou, Cheng Fang, Dejian Gu, Minxia Zhang, Mei Ji, Juntao Shi, Xin Yang
BACKGROUND: Targeted therapy has revolutionized the treatment of patients with malignancies harboring mutations in driver genes and has brought a favorable survival benefit to the population with actionable oncogenic mutations. In recent years, the MET exon14 skipping mutation has been recognized as a potentially promising therapeutic target in non-small cell lung cancer (NSCLC). These changes are mutually exclusive with molecular drivers such as EGFR, KRAS, HER-2, BRAF, ALK and ROS1...
June 23, 2022: BMC Medical Genomics
https://read.qxmd.com/read/35598358/the-impact-of-tp53-co-mutations-and-immunologic-microenvironment-on-outcome-of-lung-cancer-with-egfr-exon-20-insertions
#13
JOURNAL ARTICLE
Petros Christopoulos, Klaus Kluck, Martina Kirchner, Heike Lüders, Julia Roeper, Roger-Fei Falkenstern-Ge, Marlen Szewczyk, Florian Sticht, Felix C Saalfeld, Claas Wesseler, Björn Hackanson, Sebastian Dintner, Martin Faehling, Jonas Kuon, Melanie Janning, Diego Kauffmann-Guerrero, Daniel Kazdal, Sylke Kurz, Florian Eichhorn, Farastuk Bozorgmehr, Rajiv Shah, Amanda Tufman, Martin Wermke, Sonja Loges, Wolfgang M Brueckl, Christian Schulz, Daniel Misch, Nikolaj Frost, Jens Kollmeier, Martin Reck, Frank Griesinger, Christian Grohé, Jin-Liern Hong, Huamao M Lin, Jan Budczies, Albrecht Stenzinger, Michael Thomas
BACKGROUND: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce. PATIENTS AND METHODS: We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases. RESULTS: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, ≈7 months), which were longer compared to monochemotherapy (9%, 59%, 4...
May 19, 2022: European Journal of Cancer
https://read.qxmd.com/read/35582532/efficacy-of-icis-on-patients-with-oncogene-driven-non-small-cell-lung-cancer-a-retrospective-study
#14
JOURNAL ARTICLE
Xiaojin Guo, He Du, Jiayu Li, Menghang Yang, Anweng Xiong, Haiping Zhang, Fengying Wu
Aim: The objective of our study was to assess the efficacy of immune checkpoint inhibitors (ICIs) on patients with non-small-cell lung cancer (NSCLC) harboring oncogenic alterations. Methods: We retrospectively enrolled patients with advanced non-squamous NSCLC who were treated with anti-PD-1-based monotherapy or combined immunotherapy. Major characteristics including PD-L1 expression, treatment, and survival were analyzed. Results: In total, 309 non-squamous NSCLC patients with a median age of 61 years (range 20-88 years) including 70...
2022: Cancer Drug Resistance
https://read.qxmd.com/read/35486541/insight-into-targeting-exon20-insertion-mutations-of-the-epidermal-growth-factor-receptor-with-wild-type-sparing-inhibitors
#15
JOURNAL ARTICLE
Jonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Janina Niggenaber, Marina Keul, Fatma Parmaksiz, Matthias Baumann, Sascha Menninger, Eldar Zent, Ina Landel, Jörn Weisner, Kirujan Jeyakumar, Leonie Heyden, Nicole Russ, Fabienne Müller, Carina Lorenz, Johannes Brägelmann, Inga Spille, Tobias Grabe, Matthias P Müller, Johannes M Heuckmann, Bert M Klebl, Peter Nussbaumer, Martin L Sos, Daniel Rauh
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the development and characterization of the novel covalent inhibitors LDC8201 and LDC0496 based on a 1 H -pyrrolo[2,3- b ]pyridine scaffold. They exhibited intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations as well as selectivity over wild type EGFR and within the kinome...
May 12, 2022: Journal of Medicinal Chemistry
https://read.qxmd.com/read/35032819/amivantamab-jnj-61186372-induces-clinical-biochemical-molecular-and-radiographic-response-in-a-treatment-refractory-nsclc-patient-harboring-amplified-triple-egfr-mutations-l858r-t790m-g796s-in-cis
#16
JOURNAL ARTICLE
Misako Nagasaka, Ani S Balmanoukian, Russell Madison, Shannon S Zhang, Samuel J Klempner, Sai-Hong Ignatius Ou
The sequential use of 1st -/2nd -generation to 3rd -generation epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) has led to the emergence of triple EGFR mutations generally consisting of the founder mutation (del 19 or L858R), gatekeeper mutation (T790M) and mutation (C797S) that abolishes the covalent binding of osimertinib to the EGFR protein (i.e., del 19 or L858R/T790M/C797S). Besides C797S, other tertiary mutations confer structural steric hindrance to osimertinib rather than preventing its covalent binding to the EGFR kinase domain such as solvent front mutation (G796S) or others such as L792F/H mutation...
February 2022: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/34871271/erlotinib-combined-with-bevacizumab-and-chemotherapy-in-first-line-osimertinib-resistant-nsclc-patient-with-leptomeningeal-metastasis-a-case-report
#17
JOURNAL ARTICLE
Musen Wang, Fuxin Zhu, Ningning Luo, Mengmeng Li, Yingxue Qi, Mingbo Wang
RATIONALE: Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option for NSCLC with LM harboring epidermal growth factor receptor (EGFR) mutation. However, therapeutic approaches remain a challenge for osimertinib resistant NSCLCs with LM. Although studies have reported that the first/second-generation EGFR-tyrosine kinase inhibitors were active against osimertinib-resistant NSCLC with EGFR C797S and sensitive mutation (SM), the resistance inevitably occurred due to the development of the EGFR SM/C797S/T790M triple mutations...
November 5, 2021: Medicine (Baltimore)
https://read.qxmd.com/read/34232939/coexistence-of-a-secondary-strn-alk-eml4-alk-double-fusion-variant-in-a-lung-adenocarcinoma-patient-with-egfr-mutation-a-case-report
#18
JOURNAL ARTICLE
Qian Zeng, Han Gao, Longdan Zhang, Shouming Qin, Yongyao Gu, Quanfang Chen
ALK-positive disease is characterized by the presence of ALK gene rearrangements that encode driver fusion oncoproteins. EML4-ALK fusion is regarded as the most common type in advanced nonsmall cell lung cancers. STRN-ALK is a novel ALK fusion partner in NSCLC and is considered sensitive to targeted therapy. However, there was no study regarding effective therapy for EML4-ALK and STRN-ALK double fusion variants in EGFR-resistant mutant lung cancer. TP53, RB1, and EGFR exon 21 L858R were found in tumor tissues and plasma from patients with capture-based NGS...
September 1, 2021: Anti-cancer Drugs
https://read.qxmd.com/read/33896242/transformation-of-advanced-lung-adenocarcinoma-to-acquired-t790m-resistance-mutation-adenosquamous-carcinoma-following-tyrosine-kinase-inhibitor-a-case-report
#19
JOURNAL ARTICLE
Qinghan Liu, Lin Wu, Suning Zhang
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are recommended for patients with non-small cell lung cancer with EGFR mutations. However, acquired resistance to EGFR-TKIs seems inevitable and the mechanism of drug resistance has not been fully defined. There is no effective treatment for patients with advanced lung adenocarcinoma who are resistant to TKIs owing to pathologic type conversion. CASE PRESENTATION: We report a patient who was initially diagnosed with lung adenocarcinoma...
December 2021: Tumori
https://read.qxmd.com/read/33867182/ameloblastic-fibrosarcoma-of-the-maxilla-with-egfr-exon-20-insertions-relevance-of-whole-exome-sequencing-in-molecular-understanding-and-therapeutic-proposals-for-rare-cancers
#20
JOURNAL ARTICLE
Kazuhiro Terada, Yosuke Yamada, Yoshihiro Ishida, Takuya Yamamoto, Masahiro Kikuchi, Yasuaki Nakashima, Hironori Haga
Ameloblastic fibrosarcoma (AFS) is the most common odontogenic sarcoma, but the incidence is relatively low, and its molecular biology is poorly understood. We experienced a young female patient with a rapidly growing soft tissue tumor of the left maxilla, which eventually occupied the left side of the oral cavity. Histologically, the tumor mainly consisted of a proliferation of atypical spindle to polygonal cells without any specific differentiation, but a small number of benign odontogenic epithelial foci mainly in the tumor periphery were also noted; thus, a diagnosis of AFS was made...
December 2022: Auris, Nasus, Larynx
keyword
keyword
169958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.